The trial focuses on adults with a liver condition called Metabolic Dysfunction-Associated Steatohepatitis (often shortened to MASH). This disease causes excess fat buildup in the liver, inflammation, and can lead to scarring known as fibrosis. Diagnosis is confirmed by a tiny tissue sample called a biopsy, which is examined under a microscope.
The investigational treatment is an injectable form of efimosfermin alfa, given under the skin (subcutaneous injection). Participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the study staff know which one is given (double‑blind). The study lasts about one year, with regular clinic visits for injections and safety checks.
The main goal is to see whether the drug can improve liver health by reducing inflammation and decreasing scarring (fibrosis) compared with the placebo. Researchers will look at changes in the liver tissue, blood tests, and overall health over the treatment period.
Austria 
Belgium 
Bulgaria 
France 
Germany 
Greece 
Italy 
Poland 
Spain 
The Netherlands 